Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion description "[Patients with stage IV neuroblastoma over the age of 500 days without MYCN amplification have a survival rate of <30% and there are currently no reliable means of predicting which of these patients will survive or succumb to the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion evidence source_evidence_literature NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion SIO_000772 18765546 NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion wasDerivedFrom befree-20140225 NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion wasGeneratedBy ECO_0000203 NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- befree-20140225 importedOn "2014-02-25" NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.